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Abstract
Background: Medication non-adherence, polypharmacy, and adverse drug events are major healthcare issues
leading to significant morbidity, mortality, and healthcare expenditures. Currently, there are no methods to
systematically track medication usage in community-dwelling seniors. The eDosette prototype was created to make
medication use patterns visible via the Internet. This study aims to demonstrate feasibility, usability, and
acceptability of the eDosette in community-dwelling seniors in primary care.
Methods: A 2-week feasibility study involving a convenience sample of 10 patients from an academic family
medicine teaching unit in Hamilton, Ontario, Canada, was conducted over a 6-month period between April and
October 2015. The eDosette transmitted hourly electronic data via the Internet on each participant’s pattern of
medication use; this data was converted into an individualized medication administration record (MAR). Based on
the MARs from the 10 participants, the frequency of missed medication doses, the time of dose administration, and
each participant’s adherence rate for their prescribed medications could be determined. A medication adherence
survey and a patient usability and acceptability survey were administered to all the participants of the study.
Results: The eDosette was able to record a participant’s medication use and transmit this data electronically via the
Internet with sufficient quality to create participant-specific MARs. A total of 418 doses were captured by the
eDosette throughout the study; only 5% (n = 22 doses) were missing information or had poor image quality.
Analysis of the MARs revealed that 19% (n = 79 doses) were taken outside a 2-h window of the average dose
administration time, and two doses were completely missed by all participants during this feasibility study.
Participant feedback found the eDosette easy and acceptable to use. Participant feedback also identified hardware
and software issues that require attention prior to a larger study.
Conclusions: The eDosette is a feasible and novel technology that can be successfully installed into the homes of
community-dwelling seniors to help in monitoring actual medication use patterns. This study provided details for
further device development and evidence to support the need for a larger pilot study on the eDosette’s impact on
medication adherence.
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Background
Healthcare for senior adults (aged 65 and above) is
complex; seniors in developed countries take a median
number of seven medications [1, 2]. Medication non-
adherence, polypharmacy, and associated morbidity and
mortality from drug side effects are major and costly
problems for healthcare systems and patients. A Canadian
study in 2008 found that 0.75%, or approximately 7000, of
annual emergency department (ED) visits in Ontario alone
are due to adverse drug events (ADEs) [3]. The estimated
cost of these visits in Canadian dollars is $35.7 million per
year. Another Canadian ED study reported that 68% of
ED visits related to ADEs were preventable [4].
Medication non-adherence may be due to regimen
complexity, perceived side effects, lack of information,
forgetfulness, cost of medications, and discordance
about treatment decisions [5, 6]. Two German studies
report that community patients self-report a non-
adherence rate of 60% [7, 8]; a Chinese study reported
specifically that multi-morbidity is associated with
poorer medication adherence [9]. In acute and long-
term care settings, medications administered to patients
are recorded in a medication administration record
(MAR). For community-dwelling seniors, a MAR system
does not exist to track how medications are actually
taken. As a result, primary care clinicians often do not
have objective information on medication adherence
during clinical encounters when multiple medication
prescriptions are being renewed. Physicians are poor at
identifying which patients will be non-adherent to pre-
scribed medications [6]; expecting physicians to accur-
ately and consistently identify non-adherent patients
without objective information is not reasonable. There-
fore, having information available during medical ap-
pointments on how medications are actually used by
community-dwelling seniors would greatly assist physi-
cians in identifying those who are non-adherent and
could help facilitate treatment decisions and patient
engagement in the therapeutic discussion. Reviewing a
patient MAR together with the patient may also help
clinicians and patients identify individual patient-specific
barriers to improving adherence.
The interventions for medication adherence studied in the
literature can be classified as either directly or indirectly
measuring medication adherence. These interventions range
from simple interventions, such as blister packs or dosettes
(BP/Ds), to more complex multi-faceted interventions
involving behavioural and educational strategies [10–12]. In-
terventions that directly measure adherence (e.g. direct ob-
servation or serum drug levels) are often expensive,
impractical, and limited to a single medication [13] while in-
terventions that indirectly measure adherence (e.g. patient
questionnaires, pill counting, pill organizers, medication
schedules) are plagued by potential bias, false assumptions,
and lack of patient engagement and can also be costly [6,
14]. However, there is some evidence that BP/D and other
pill organizers increase the percentage of medication pills
taken [15].
Incorporating technology is one method to potentially
enhance these packaging systems that track medication
administration. For example, one device electronically
monitors the opening of a pillbox compartment [16],
while another intervention provides a custom blister pack
enhanced with micro-circuitry to track when a compart-
ment has been punched [17]. These technology-enhanced
systems are able to provide objective information on
indirect medication adherence; however, their impact on
medication adherence has not been adequately studied.
Other technology-mediated interventions involve
patient education and self-monitoring to improve medi-
cation adherence, with a small proportion focusing on
electronic reminder interventions to improve patient ad-
herence [18]. Currently, the main electronic reminder
interventions studied are pillboxes with lights and
alarms [18]. However, these technology-mediated inter-
ventions have not been designed to foster patient en-
gagement in making decisions about their medication
regimens. These interventions are also not tethered to a
secure online communication method with their primary
care team nor with a reporting system for potential side
effects. For elderly patients taking multiple chronic medi-
cations, interventions with increased physician communi-
cation are often necessary to improve adherence [19, 20].
Family physicians are often unaware of medication tak-
ing and non-adherent behaviours because of a lack of
physician-patient dialogue in community-dwelling se-
niors [21]. In one primary care study, the least discussed
topics in medical encounters include potential side ef-
fects, patient attitudes towards current medications, and
compliance [22]. The eDosette, the technology-mediated
medication adherence intervention presented in this
study, was developed to address this primary care know-
ledge gap regarding the medication use behaviours of
older patients. The eDosette is an Internet-enabled de-
vice that can monitor medication taking in a patient’s
home by sending pictures every hour of the patient’s BP/
D to the healthcare provider. The information can then
be used to generate the MAR to observe their patient’s
medication taking habits. The eDosette is compatible
with and can monitor existing BP/Ds, thus eliminating the
barrier of requiring patients to use a customized BP/D.
The eDosette was also designed with a method for enab-
ling patient engagement and communication through the
Internet about their medications, their medication adher-
ence, and potential side effects.
The eDosette device has the potential to be widely
used by Canadian seniors despite the fact that it requires
an Internet connection. In 2012, the rate of Internet
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access in Canadian households is 83%, and 59% among se-
niors. Internet use among seniors in Canada is similar to
rates reported in the USA by the PEW Research Centre
[23, 24]. Nevertheless, one third of the senior population
may not have home Internet; however, Internet access can
be made easily available with a cellular hot spot device.
The primary research aims for this feasibility study were
to test the eDosette prototype in a primary care setting to
determine whether the eDosette could capture and reliably
transmit patient medication administration information with
sufficient quality over the Internet, to create specific patient
MARs detailing actual patterns of medication use, to deter-
mine whether the eDosette could transmit potential drug
side effect alerts (SEAs) over the Internet, and to identify
the technological, hardware, and software issues that may
inform future prototype improvements. Additional research
aims were to elicit participant feedback about the usability
and acceptability of the eDosette and to compare a patient’s
actual medication adherence rate to their self-rated medica-




This was a feasibility study of the eDosette in community-
dwelling seniors in primary care, conducted between April
and October 2015. The intervention lasted 2 weeks, a time
frame that was deemed sufficient to determine techno-
logical (e.g. data capture and transmission, creation of
MARs, Internet connectivity) and user-related issues asso-
ciated with implementing the eDosette in the home.
Study population
A convenience sample of 10 patients was recruited from
three family practices at an academic family medicine
teaching unit in Hamilton, Ontario, Canada. The inclu-
sion criteria were as follows: age 65 and over, taking five
or more medications, and using or willing to use a BP/
D. Patients with a diagnosis of mild cognitive impair-
ment or dementia were excluded. Potential patient par-
ticipant lists were generated for the three family
practices in the teaching unit; the family physicians iden-
tified and approved the patients who were then con-
tacted by telephone for interest in participation by our
research assistant (RA). A total of 45 patients were iden-
tified and contacted for interest to participate; of these,
35 patients declined participation, resulting in a recruit-
ment rate of 22%. The primary reasons for declining par-
ticipation during initial telephone contact were lack of
interest in participating in general research activities or
lack of time. Only two patients declined participation
during the first home visit after seeing the device. In one
case, their blister pack was too large to fit in the device
and the patient declined an alternative compatible
device. The second patient declined because they often
brought their dosette out of the home (i.e. carried it with
them), so their medication administrations could not be
accurately monitored. Patient self-perceived competence
with using and learning new technology was not an in-
clusion or exclusion criterion for participation.
Description of the eDosette prototype
The eDosette device consists of a digital image sensor
controlled by a low-cost computer (Raspberry-Pi [26]).
The eDosette has a designated compartment where a
participant’s BP/D is stored between dose administra-
tions; the image sensor takes serial hourly pictures of the
stored BP/D. This continuous longitudinal image data
on medication administration is sent via the Internet to
the eDosette web-application server where it is accessed
and converted into a patient-specific MAR. The
eDosette is also equipped with an SEA button, which
can be pressed by the patient to indicate to their primary
care team about perceived drug side effects in real time.
Lastly, a medication disposal unit is included in the
prototype; patients can dispose of their unused medica-
tions into this unit.
Study procedures
The first-generation eDosette prototype consists of two
versions, a bottom-loading and a top-loading model, to
test which design produced higher quality images of the
BP/D. Five participants were assigned to the bottom-
loading version, and the other five were assigned the
top-loading version. Assignment of prototype was based
on availability of a top-loading or bottom-loading ver-
sion upon enrolment in the study. The RA visited each
participant’s home to set up the eDosette prototype,
provide patient instruction on using the device (e.g. how
to load the BP/D into the eDosette, the location, and
function of the SEA button, and the eDosette’s medica-
tion disposal unit), and assist in finding a suitable loca-
tion for the eDosette. Overall, the time required for
education, set-up, and installation was approximately
20 min per participant. Participants were asked to take
their medication according to their usual routine. The
RA inspected all the BP/Ds to ensure compatibility with
the eDosette; if incompatible, participants were offered a
self-fill blister pack or a selection of compatible dosettes
for use during this study. Participants managed and
stored their medications in the eDosette independently for
the length of the trial; this included filling their dosette
with the week’s pills or switching out new and old blister
packs. All participants were offered the use of a cellular
hot spot device to standardize data transmission.
The eDosette was installed in each participant’s home
for 2 weeks. The device took an image of the stored BP/D
every hour, and the RA used these images to infer when a
Siu et al. Pilot and Feasibility Studies  (2017) 3:5 Page 3 of 11
medication dose was taken. The RA then created a MAR
report for each participant, and a second independent
coder verified the MARs. The RA performed all data
collection. After 2 weeks, the participants were asked to
complete a feedback survey, the MAQ [25], and had an
exit interview comprised of three questions with the RA
about their opinion of the usability and acceptability, as
well as their experience with the eDosette prototype.
Outcome measures
Primary outcomes
The primary outcomes consisted of the rate of data cap-
ture and transmission over the Internet by the eDosette
in the 10 participants, the frequency of SEAs generated,
the difference in image quality between the bottom-
loading and top-loading first-generation eDosette proto-
types, and the identification of technical, hardware, and
software issues that arose during installation and use.
Secondary outcomes
The secondary outcomes consisted of participant
feedback on usability and acceptability, actual participant
adherence to prescribed medications determined by
preliminary analysis of MARs, and a comparison of par-
ticipant medication adherence rates as reported by the
eDosette MARs to participant self-rated medication
adherence on the MAQ [25].
Data collection and analysis
Each participant’s MAR was reviewed to determine the
approximate time of medication administration, the
frequency of missed medication doses, and the average
variation in timing of each dose administration. Deter-
mining the exact time of dose administration was not
possible as the eDosette captured images on an hourly
basis; therefore, there was no method of determining
whether a dose was taken at the beginning or end of
the hour (e.g. 09 h05 vs. 09 h55). For this study, medi-
cation adherence was defined as the percentage of
doses actually administered within a 2-h time window
of the average dose administration time; this was based
on a previously published definition from electronic
adherence monitoring of a single medication that used
variation in medication dose timing [27]. Based on
this published definition, the investigator group mutu-
ally decided that a missed dose or a dose taken 2 h
outside the average time of dose administration would
be deemed as a significant variation in medication
administration.
Participants were asked to complete three items at the
end of the study: the four-item MAQ [25], a structured feed-
back questionnaire, and a very brief interview. The MAQ
has been validated in the outpatient setting [28]. The adher-
ence data from the MAR and the participants’ self-rated
medication adherence are presented descriptively.
The feedback questionnaire for this study was modeled
from an existing survey seeking user feedback after the
implementation of a new technology in a healthcare set-
ting [29]. This survey was organized to seek feedback on
different domains relevant to evaluating the implementa-
tion of a technology in a new setting. The investigator
group adapted relevant questions from this survey to use
in our eDosette feedback survey, and questions were
grouped under six categories: purpose, implementation
and usability, impact on daily routine, acceptability for
future use, personal opinion, and patient enablement
(Table 1). We did not validate the survey in our popula-
tion. Quantitative survey responses were coded as fol-
lows: −2 = strongly disagree, −1 = disagree, 0 = neutral,
+1 = agree, and +2 = strongly agree.
Table 1 Description of the feedback categories included in the participant feedback survey
Feedback category Description
Purpose The investigator group was interested to know whether participants felt the eDosette was able to support
participants in managing their medications based on their experience in the 2-week study.
Implementation and usability The investigator group was interested to know how easy it was for community-based seniors to learn and
use the eDosette successfully. In this context, understanding whether the initial meeting and education
provided by the RA was sufficient to allow the participant to use the eDosette for the study.
Impact on daily routine The investigator group was interested to understand the perceived impact of the eDosette on the
participants’ lives and roles as patients with respect to medication management.
Acceptability for future use The investigator group was interested to know whether participants would use the eDosette in the future,
outside of the research context. Specifically, understanding whether the technology was a barrier to future
acceptability and future use was of interest.
Personal opinion The investigator group was interested in gaining the personal opinion of participants especially in their
perception of whether the eDosette would negatively impact their therapeutic relationship with their
healthcare team. Furthermore, the participants were asked to express their satisfaction with the device overall.
Additional personal opinions and feedback were elicited during the exit interview with the RA.
Patient enablement Patient enablement includes confidence and self-efficacy. For the sake of this study, the investigator group
was particularly interested in whether the eDosette could result in increased confidence in medication
management in our participants.
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After the study was completed, the RA asked the par-
ticipants three interview questions, “What were the
three best aspects of the device? The three worst?” and
“Do you have any other comments?”. The RA wrote
down the responses and clarified the comments with the
participant if needed. Participants did not have to supply
three answers to each question if they were unable to
identify three distinct answers.
Throughout the study, the RA kept a running list of any
technical, hardware, or software issues that required dis-
cussion and attention among the study team. Minor issues
that did not impact the overall design and construction of
the prototype were dealt with in real time; for example,
longer extension cords were purchased so that possible
eDosette locations would not be restricted by proximity to
electrical outlets. Issues that would require additional re-
sources or time would be addressed during next-
generation prototype development. Both minor and major
issues were recorded on an electronic spreadsheet.
Results for medication adherence are presented as
mean (minimum-maximum) for continuous variables
and as number or percent of participants for categorical
variables. For the participant feedback survey, a mean
score was calculated for each survey question; a positive
mean response indicated agreement with the statement,
and a negative mean response indicated disagreement. A
formal qualitative analysis was not completed on the par-
ticipants’ responses from the exit interview; frequency of




The demographic information for all 10 participants are
listed in Table 2. All participants had stable medication
regimes during the 2-week study, with no new initia-
tions, titrations, or discontinuations. A total of 418 dose
administrations were captured. Information was missing
for 22 doses (5%) due to issues with data capture and
image quality. Software was initially developed to
automatically generate MARs from the transmitted data.
However, the software was not able to accurately gener-
ate MARs from the data being sent from the partici-
pants’ eDosette; likely contributing reasons have been
listed in Table 3. As a result, each participant had their
2-week MAR created manually from the transmitted
data. To view a sample MAR report, see Table 4. No le-
gitimate SEAs were generated during the 2-week study
by any of the 10 participants. One participant initially
triggered an SEA each time a medication dose was
taken; during follow-up regarding these alerts, it was re-
vealed that the participant had mistakenly understood
the function of the SEA button. After this misunder-
standing was corrected, no additional inappropriate
SEAs were generated.
eDosette prototype evolution
The two first-generation prototypes used in this feasibil-
ity study had participants store their BP/D into the eDo-
sette via a bottom-loading (Fig. 1a) or a top-loading slot
(Fig. 1b). Half the participants used the bottom-loading
model, and the other half used the top-loading model.
After analyzing the images captured and transmitted by
both prototypes, it was decided that the top-loading
first-generation model captured images with better qual-
ity. This was likely a result of the top-loading prototype
design, which minimizes the distance between the par-
ticipants’ BP/D and the digital image sensor. The top-
loading first-generation model also accommodated a
wider range of BP/D types when compared to the
bottom-loading model. Furthermore, the bottom-loading
slot made it difficult for participants to consistently in-
sert the BP/D adequately into the eDosette to allow for
good image capture, and the slot made retrieval of a
smaller BP/D difficult. Additional hardware, software,
and participant-related issues identified during this feasi-
bility study for both first-generation models are listed in
Table 3.
The issues presented in Table 3 led to the develop-
ment of a top-loading, second-generation model of the
eDosette (Fig. 1c). This second-generation prototype was
designed and constructed to address issues including
blocking out ambient lighting, reconfiguring the storage
area to accommodate BP/D of any size or type, and im-
proving the physical aesthetics and size of the eDosette.
An example of the image data captured and transmitted
is shown under each respective prototype in Fig. 1d–f.
The second-generation top-loading model will be the basis
for the future planned study on the eDosette prototype.
Secondary outcomes
Medication adherence rates
Overall, two doses were not taken (i.e. missed) by all 10
participants, and a total of 79 doses (19%) were




Mean age (years, minimum-maximum) 75 (65–87)
Mean number of prescription medications
(minimum-maximum)
7.7 (5–10)
Type of medication storage aid (n)
Dosettes (self-filled) 5
Blister packs (pharmacy) 4
Pill bottles (switched to dosette for the study) 1
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administered outside a 2-h window of the average
dose administration time (e.g. a dose taken outside
08 h00–10 h00 for a 09 h00 average dose time).
Figure 2 reports observed medication adherence in
relation to the number of daily dose administrations
and participant MAQ scores. A pattern was observed
between the participants’ medication adherence and
the number of daily dose administrations; participants
with a higher number of daily doses were observed to
have lower actual medication adherence as deter-
mined by the eDosette. As well, the MAQ score (a
higher score indicating higher self-rated medication
adherence) was not entirely consistent with the medi-
cation adherence reported by the eDosette.
Participant feedback survey
On average, participants did not agree with the state-
ment that the eDosette would get them in trouble with
their primary care team (mean −1.40) or that having the
eDosette in the home felt like someone was watching
the participants take their medications (mean −0.70)
(Table 5). The mean rating for ease of the use of the
technology was 1.20. Mean overall satisfaction with the
eDosette was rated 0.50. There was some agreement that
the eDosette offered participants a way to be involved in
their medications (mean 0.40) and that having an
eDosette would positively impact confidence in taking
medication correctly (mean 0.60).
Responses were coded as follows: strongly disagree =
−2, disagree = −1, neutral/did not apply = 0, agree = 1,
and strongly agree = 2. Mean scores were then calculated
for each question; positive responses indicate an agree-
ment with the statement, while negative responses indi-
cate a disagreement with the statement.
Participant feedback from interviews
Participants were asked to list the three worst and best
aspects of the eDosette after the trial was completed and
to give any other comments about the experiment or de-
vice. The RA recorded these responses, and several com-
mon comments were identified. The most commonly
reported positive aspect, mentioned by half of the partic-
ipants, was that the eDosette was a consistent place to
keep medications and served as a visual reminder for the
participant to take their medications. Two participants
commented that the eDosette was easy to use. Two par-
ticipants said that the eDosette helped them realize that
they were missing doses, which one said led to better
medication taking habits. All participants except one re-
ported positive feedback; the one participant exception
only had one daily medication administration. This
Table 3 Hardware, software, and participant-related issues identified for the eDosette prototype during this feasibility study
Hardware issues - Could not completely eliminate ambient light from outside the eDosette (major issue)
- Could not accommodate all sizes of BP/D currently available on the market (major issue)
- The length of the power cord impacted the possible locations of the eDosette in the
home (minor issue)
Software issues Photo-recognition software
- Incompatible with some BP/D construction material resulting in poor quality images from
the eDosette camera (major issue)
- Required BP/D placement in the eDosette to be fixed in a specific location in order for the
software to correctly analyse the captured image (major issue)
- Could not accurately identify the specific number medications within the BP/D compartment
due to the random stacking of medications in the compartment (major issue)
Side effect alerts (SEAs)
- Some SEAs were sent to the research team by the device without being triggered by the
participant (minor issue)
Participant-related issues - Triggering inappropriate SEA alerts due to misunderstanding the role of the SEA button
(minor issue)
- Location of BP/D storage for some participants changed as a result of having to locate the
eDosette in the participant homes near a wall electrical outlet (minor issue)
Table 4 A sample participant medication administration record
Day of study
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Mean dose time VAR (in hours)
Time of dose (24 h time) Dose 1 10 10 10 7 X 13 16 8 9 11 16 14 9 9 9 11 8.2
Dose 2 17 15 17 20 X 13 16 16 14 20 16 14 9 16 X 16 8.3
Dose 3 20 21 20 20 X 22 21 20 20 20 21 X 20 21 X 20 h30 0.45
A participant medication administration record (MAR) showing the time each dose was administered as determined by the images captured by the eDosette. The time
listed for each dose administration is in 24 h time (e.g. 20 = 20 h00 = 8:00 pm) and reflects the time of the image when the blister pack or dosette compartment is
noted to be empty or partially empty. In this MAR, the “X” indicates missing images. The mean dose time reflects the average time of a particular dose administration
over the 2-week study period, rounded to the half hour. Statistical variance (VAR) in the times for each dose was calculated and reported as well
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Fig. 1 The various iterations of the eDosette prototype and their corresponding image data. a The first-generation, top-loading eDosette prototype
that includes a side effect alert button and a medication disposal unit. b The first-generation, bottom-loading eDosette prototype that includes a side
effect alert button and a medication disposal unit. c The second-generation, top-loading eDosette prototype that includes a side effect alert button
and a medication disposal unit. d An example of the image captured by the first-generation top-loading eDosette prototype. e An example of the
image captured by the first-generation bottom-loading eDosette prototype. f An example of the image captured by the second-generation top-
loading eDosette prototype
Fig. 2 Participant medication adherence during the feasibility study. Comparing medication adherence (i.e. the percentage of administered doses
taken within the 2-h time window of the average dose administration time) data to number of daily dose administration for all 10 participants.
The Medication Adherence Questionnaire [25] scores for each participant is also shown (0 = low self-rated adherence, 1–2 =medium self-rated
adherence, 3–4 = high self-rated adherence)
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participant felt that the eDosette did not add to their
ability to take their medications.
The participants also identified other negative aspects
about the eDosette. Upon seeing the device, all of the
participants felt that it was large, and four mentioned
this issue in the end interview. Three participants were
also discouraged by the inability of bringing the device
with them when they were out of their homes. Two par-
ticipants wanted the device to be able to fit more medi-
cations, such as weekly doses, as needed doses or
vitamins that were not in their blister pack. One partici-
pant was uncomfortable with the idea that medication
use was being monitored and felt that the device was
very “big brother.”
Discussion
We conducted a pilot study of the feasibility and accept-
ability of a device that would send images of BP/Ds of
10 senior adults to the research staff via the Internet
over a 2-week period. The recruitment rate was 22%; of
those declining participation, most were not interested
in research activities in general and the other reasons for
declining are outlined previously. This study demon-
strated that the eDosette could capture and make visible
actual medication use patterns 95% of the time and re-
ported an objective participant medication adherence
rate ranging from 64 to 100%. Our observed range is
consistent with adherence ranges reported in literature,
which are largely based on self-reported adherence mea-
sures such as the MAQ [19, 30].
The 2-week trial provided evidence that the technol-
ogy, even in its rudimentary development stage, was
feasible to set up and install in the home of community-
dwelling seniors. Setting up the eDosette in participants’
homes required several modifications, such as providing
a cellular hot spot device and switching BP/D packaging
to be compatible with the first-generation eDosette proto-
type. The latter issue has been addressed in the second-
generation prototype shown in Fig. 1c that has been de-
signed to accommodate the majority of existing BP/Ds.
The former issue is a consideration for future prototypes
since incorporating a cellular hot spot device into the
eDosette could easily be done; however, the cost of this
modification and the Internet bandwidth required will
need to be assessed in future studies prior to making the
addition of cellular hot spot devices a permanent feature
on the eDosette. A partnership with telecommunication
companies could help reduce this cost and increase the
quality of the data transmitted.
Overall, participants only required a short amount
of time with the RA, approximately 20 min, to iden-
tify a suitable location for the eDosette, become fa-
miliar with the device, and successfully use the
eDosette for the 2-week study. Participants found the
eDosette easy to use and were not worried about the
implications of having their primary care team aware
of their medication adherence. Interestingly, partici-
pants did not strongly endorse statements about the
eDosette’s ability to help them take a more active role
in their medication use or increase their confidence
in using their medication; this was likely due to the
Table 5 Participant feedback survey responses for the eDosette clustered by feedback domain
Mean score (min, max) Feedback survey statement Feedback domain
0.40 (−1, 2) The eDosette helped me to take my medication more correctly than before. Purpose
0.30 (−2, 2) The eDosette made taking my daily medications less confusing. Purpose
1.20 (0, 2) I found the eDosette easy to use. Implementation and usability
1.00 (0, 2) Training in the use of the eDosette was adequate for me to use it effectively. Implementation and usability
−1.10 (−2, 0) I had problems maintaining and taking care of my eDosette. Implementation and usability
0.40 (−2, 2) The eDosette allowed me to have a more active role in my medications. Impact on daily routine
0.20 (−2, 2) The eDosette made it easier to remember to take my medications. Impact on daily routine
−0.10 (−2, 2) The eDosette made my daily medication routine easier. Impact on daily routine
−0.10 (−2, 2) With the eDosette, I will rely less on my pharmacy to organize my medications. Impact on daily routine
0.60 (−2, 2) I would use the eDosette in the future if it were offered. Acceptability for future use
−0.60 (−2, 1) Problems with the eDosette technology would prevent me from using it in the future. Acceptability for future use
0.50 (−2, 2) I am satisfied with the eDosette overall. Personal opinion
0.38 (0, 2) I feel that with the eDosette, I can now be honest with my family doctor about medication. Personal opinion
−0.70 (−2, 1) The eDoesette feels like someone is always watching me when I use medication. Personal opinion
−1.40 (−2, 0) I worry the eDosette may get me in trouble with my family doctor. Personal opinion
0.60 (0, 2) Did the eDosette increase your confidence in taking medication? Patient enablement
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fact that the study was focused on testing the
eDosette hardware and software. This study was not
designed to evaluate whether the eDosette MAR, in
conjunction with any resulting clinical communication
resulting from reviewing the MAR, would better en-
able or build confidence in participants while man-
aging their own medications or impact clinical health
outcomes.
Even in this small group of participants, the eDosette
was able to detect variation in medication taking behav-
iour that could have implications for effectiveness of the
medications. Varying the time of administration within a
2-h window for a medication that is dosed once daily is
unlikely to impact the effectiveness of this medication
for treating its associated condition. However, this same
variation in a multiple daily dosed medication (e.g. the
morning dose being taken at 10 h00 vs. 08 h00 and the
afternoon dose is taken at 12 h00 vs. 14 h00) may poten-
tially impact the effectiveness of a medication resulting
in possible ADEs and participant side effects. Further-
more, the pattern between medication adherence and
the number of daily dosages observed in our participants
is consistent with findings in the existing literature dem-
onstrating an association between the number of times a
day a participant needs to take medications and partici-
pant non-adherence to medication regimens [31].
Eight of the participants had an MAQ score of three
or higher (Fig. 2), which would indicate good self-rated
adherence; however, the range of observed medication
adherence in these eight participants ranged from a low
of 64% to a high of 100%. This may be a result of the
narrow range of possible scores on the four-item MAQ,
where each MAQ score may span a wide range of actual
observed medication adherence rates. A validated eight-
item MAQ exists with a wider range of possible scores;
using the eight-item MAQ in a larger study sample may
reveal better correlation between a participant’s self-
rated and observed medication adherence. Our reported
adherence rate is higher than the 47% adherence rate re-
ported in a previous study in senior adults [32]. This
study defined adherence dichotomously with a MAQ
score of four, as being adherent, and any other score was
deemed non-adherent [32]. The MAQ was not designed
to be a dichotomous measure [28], and this could con-
tribute to why our reported adherence rate lacked con-
gruence with previously published adherence rates.
Furthermore, the previous study did not compare
MAQ scores to objective medication adherence data to
validate their definition of adherence [32]. A future
planned trial of the eDosette, which would include a
larger and more representative sample of community
dwelling seniors, could potentially report a more accur-
ate estimation of medication adherence rate in these
seniors.
Limitations
The participants in this study were a convenience sam-
ple and therefore not randomly selected; as a result,
these 10 participants are unlikely to represent the entire
spectrum of the senior adult population taking multiple
medications. However, as the primary goal of the study
was to show that the eDosette could be used in the
home to accurately capture and transmit usable image
data about medication administration, a truly represen-
tative sample of the senior adult population was not ne-
cessary at this stage. Our small sample size may not
have been large enough to identify all the issues affecting
eDosette usability and acceptability; however, the investi-
gator group felt that 10 participants would be sufficient
to identify the major issues for the eDosette prototype
and inform future prototype development.
Despite the low rate of recruitment, our recruitment
strategy was sufficient to recruit the number of partici-
pants required for this feasibility study. The reasons
given for non-participation may not be reflective of the
lack actual participant interest in the eDosette technol-
ogy but with a lack of time and interest in participating
in research in general. As a result, it was not deemed ne-
cessary to utilize other methods of recruitment for this
study. It is anticipated for the future trial that other
strategies will be required; these include collaborating
with clinical pharmacists to identify participants, as well
as using a generic invitation letter strategy, which is less
resource intensive and has been successful in recruit-
ment for other projects led by various members of the
investigator group.
The participant exit interview was not a formal quali-
tative semi-structured interview. The questions posed to
the participants may not have allowed for participants to
fully express their opinions regarding usability and ex-
perience with the eDosette. However, in conjunction
with the structured feedback survey, the investigator
group felt that the participants were given sufficient op-
portunity to express their strongest opinions on the
eDosette device.
No participants experienced SEAs during the trial;
therefore, we could not evaluate the potential of the de-
vice to identify side effects experienced by the partici-
pants. The lack of reported side effects in this feasibility
study could be due to the fact that none of the partici-
pants started new medications during their involvement
with the study. The apparent lack of clinical decisions
resulting from the eDosette MARs in this feasibility
study was because the research team reviewed the
MARs only to assess the function of the eDosette tech-
nology. If the primary care clinicians most involved in
the care of the participant had reviewed the MARs in-
stead, it would be possible that clinical issues with medi-
cation regimens would have been identified. Clinician
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involvement and shared decision-making with patients
would be one of the key features and outcomes of the
future planned trial of the eDosette.
Lastly, the custom photo-recognition software initially
designed for the eDosette worked well to generate
MARs on standardized laboratory images that were cre-
ated with controlled lighting and consistent BP/D place-
ment. The software was not able to perform accurately
with images captured by the eDosette in participants’
homes. As a result, the research team decided to have
two independent reviewers code and manually generate
each participant’s MAR for the purposes of this feasibil-
ity study. As a result of this adjustment, the research
team was not able to truly evaluate how the software
performed in automatically generating participant
MARs. Although the manually generated MARs for this
feasibility study provided accurate medication adherence
information, this was at the expense of increased analysis
time and would need to be addressed if the eDosette
was to be used widely in the community-based setting.
With the creation of the second-generation prototype,
which addresses the lighting and placement issues iden-
tified in the first-generation eDosette, the development
of accurate custom software is expected.
Conclusions
Our study demonstrated that the novel eDosette tech-
nology is able to capture and transmit image data of
a participant’s BP/D and that the technology can be
installed and function in a participant’s home with
minimal support. Further work needs to be done to
develop software that will automate the MAR gener-
ation process, which would significantly improve the
clinical usability of the eDosette. This work will be
addressed in anticipation of a planned future trial of
the eDosette. Lastly, participant feedback and tech-
nical issues identified in this feasibility study will lead
to further improvements of the eDosette prototype
for future trials.
Based on the results of this initial feasibility study, a
future trial of the eDosette has been planned, which will
include a larger, more diverse sample; will leave the eDo-
sette installed in the home for a longer time period; and
will incorporate primary care clinician involvement.
Tracking medication adherence and overall medication
complexity could be potential outcome measures for this
future trial. Participant chart reviews before enrollment
in the study and then prospectively throughout the study
would allow several other possible outcome measures to
be assessed. For example, quantitatively tracking the
number of medical appointments or telephone conversa-
tions about medication issues specifically could reveal
whether the eDosette would impact patient engagement
with their primary care clinician. Another example
would be tracking the frequency and nature of medica-
tion changes during the trial; this could provide informa-
tion about the types of therapeutic medication decisions,
such as dose tapering or dosage time changes, that may
be common in the elderly population.
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